Oncology
For years, Sara worked in a hospital, making care possible for others. Now, after being diagnosed with breast cancer, she was the one in need of care.
Explore end-to-end solutions throughout development — from portfolio optimization and regulatory strategy, to Phase I-IV clinical trials, market access planning, and more.
See solutionsWHAT WE DO
HOW WE DO IT
Utilize our expertise across therapeutic areas, combining innovative trial designs, leading clinical and regulatory expertise, global reach, and a passion for changing patient lives.
See expertiseTherapeutic Expertise
Cross-Therapeutic Expertise
Our experts help you stay at the forefront of the industry - and ahead of change.
See insightsNew Medicines, Novel Insights
Discussions on Diversity
Thinking about joining a clinical trial? Learn the drug development process, what it’s like to participate, how to find a trial, and answers to frequently asked questions.
Learn moreFor years, Sara worked in a hospital, making care possible for others. Now, after being diagnosed with breast cancer, she was the one in need of care.
It took 10 years of treatments for Anisha's IBD to enter remission. But it came back in 2019 — and just as she was about to start treatment, the pandemic hit.
Want to collaborate with us to offer clinical trials at your site? We would welcome the opportunity to discuss.
Learn moreWe are one of the largest CROs in the world, speeding life-changing medicine to market by engaging patients With Heart™. Learn about who we are, what we do, and what we believe.
About ParexelWhat can we help you find today?
By Natasha Steyn, Executive Director, Global Clinical Operations
By Stella Davis, Senior Manager, Regional Feasibility Network
Australia offers a highly favorable environment for drug research and development, with a mature infrastructure and experienced, capable local resources and expertise. Considering global geopolitical uncertainties, Australia presents a compelling option for sponsors to consider. This first article in a three-part series illustrates the Australian economy, demographics, healthcare investments and expenditures, and the growth of the pharmaceutical market and clinical trials. Ensuing articles will explore the landscape for clinical trials, including the therapeutic areas, the strength of patient centricity and innovation adoption, and the regulatory and reimbursement environment.
Interested in more? Check out part 2 and part 3.
Related Insights
Blog
A hybrid model supports globally diverse site participation for a retrospective cancer study
Jul 24, 2023
Article
Can Chinese Phase I data from the West accelerate China drug development?
Mar 17, 2021
Video
Part Four: Gaps to fill with diversity and inclusion in clinical trials
Aug 17, 2021
Article
3 ways to incorporate DE&I in your communications strategy
Sep 29, 2021
Blog
Highlights from ISMPP Asia Pacific Meeting 2021
Sep 20, 2021
Video
Part One: Gaps to fill with diversity and inclusion in clinical trials
Aug 17, 2021
Video
Part Three: Gaps to fill with diversity and inclusion in clinical trials
Aug 17, 2021
Video
Part Two: Gaps to fill with diversity and inclusion in clinical trials
Aug 17, 2021
Article
India, the Generic Manufacturing Powerhouse, Biosimilar Next?
Jul 21, 2021
Article
Evidence Generation Strategy under Germany’s Digital Healthcare: Is More Better?
Aug 6, 2021
Blog
CNS Summit Recap: The Future is Collaborative
Nov 22, 2021
Article
Lessons from China and the United States on the use of RWE in regulatory submissions
Jul 19, 2021